Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Mesothelioma

Add ILCN as a preferred source
  • Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma

    Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma

    By

    Fred Gebhart
    Evolving Standards of Care, Mesothelioma, WCLC News

    Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.

  • Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

    Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

    By

    Mesothelioma

    Approximately 10% of “real-world” patients with malignant pleural mesothelioma (MPM) benefitted from checkpoint inhibitor therapy with nivolumab, according to the results of a trial presented by Robert A. Belderbos, MD, of Erasmus Medical Center, the Netherlands, during OA09: Mesothelioma from Pathogenesis to Therapy. MPM is an uncommon cancer with low survival rates between 9 to…

  • Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

    Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

    By

    Mesothelioma, WCLC 2020 Archive

    The largest real-world cohort study of individuals with malignant pleural mesothelioma (MPM) found a median survival duration of 8 months regardless of whether patients received first-line treatment with cisplatin-based chemotherapy or carboplatin-based chemotherapy (OA09.05). This bodes well for patients with MPM, who are often elderly, frail, and unable to tolerate cisplatin. “For MPM patients who…

View ILCN Archives

Provider Resources

Popular Articles

  • Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

  • Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

  • Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

  • No “Known” Risk Factors: The Health Consequences of Radiation Therapy

  • Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

  • No PFS, OS Benefit Seen in Final Results from PACIFIC-2

  • WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

  • Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

  • A Holistic Approach to Patient Care